The complex analysis of risk factors, influencing on the progression of chronic obstructive ulmonary disease


Cite item

Full Text

Abstract

Aim.The aim of the study is the analysis of risk factors, influencing on the progression of chronic obstructive pulmonary disease. Materials and methods. 259 patients with chronic obstructive pulmonary disease (COPD) I and III stages, mean age 54,3±11,7 and the duration of the disease 10,1±5,7. Patients were divided into 2 groups: I group (n=119) - with III stage of disease, II group (n=140) - COPD with I stage. 30 healthy were involved in control group. The risk factors of progression of COPD were determined with the use of regressive and correlative analyses. Results. The level of markers of systemic inflammation in serum of patients with COPD: TNF-α (RR 3,25); IL-8 (RR 2,1); hs-CRP (RR 3,52) in combination with traditional risk factors (long course of the disease (RR 2,3), age (RR 1,65), smoking (RR 1,65), and also obesity (RR 2,45), early menopause (RR 3,52), hereditary respiratory predisposition (RR 3,05), and also coexisting cardiovascular pathology increase the risk of COPD progression several times. Conclusion. According to the results of this trial, unmodified risk factors such as hereditary predisposition, early menopause, long course of the diseases and coexisting cardiovascular pathology contribute significantly on progression of COPD. The relative risk increases with increasing of concentration of markers of systemic inflammation (TNF-α, IL-8 and hs-CRP),that correlate with clinical manifestations of COPD: cough, shortness of breath on VAS in mm.

About the authors

V A Nikitin

N.N. Burdenko Voronezh State Medical University

к.м.н, ассистент каф. терапии ИДПО ВГМУ им. Н.Н. Бурденко

I A Starodubtseva

N.N. Burdenko Voronezh State Medical University

Email: starodubtsevairina1@gmail.com
к.м.н., ассистент каф. пропедевтики внутренних болезней

L V Vasilieva

N.N. Burdenko Voronezh State Medical University

д.м.н., проф., зав. каф. терапии ИДПО ВГМУ им. Н.Н. Бурденко

A V Popov

N.N. Burdenko Voronezh State Medical University

аспирант каф. пропедевтики внутренних болезней

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. National Heart, Lung, and Blood Institute. Update 2011. www.goldcopd.com.
  2. Wise R.A. The value of forced expiratory volume in 1 second decline on the assessment of chronic obstructive pulmonary disease progression. Am J Med. 2006;19(10):4-11.
  3. Мамаева М.Г, Демко И.В., Вериго Я.И., Крапошина А.Ю., Соловьева И.А., Хендогина В.Т. Маркеры системного воспаления и эндотелиальной дисфункции у больных хронической обструктивной болезнью легких. Сибирское медицинское обозрение. 2014;1(85):12-19.
  4. Koarai A, Sugiura H, Yanagisawa S, Ichikawa T, Minakata Y. Matsunaga K, Hirano T, Akamatsu K and Ichinose M. Oxidative Stress Enhances Toll-Like Receptor 3 Response to Double-Stranded RNA in Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology. 2010; 42(6): 651-660. doi: 10.1165/rcmb.2008-0345OC.
  5. Andreas S, Hering T, Muhlig S, et al. Smoking cessation in chronic obstructive pulmonary disease. Dtsch Arztebl Int. 2009;106(16):276-282. doi: 10.3238/arztebl.2009.0276
  6. Цветкова О.А., Воронкова О.О. Динамика провоспалительных цитокинов ИЛ-6 и ФНОα в сравнении с неспецифическими маркерами воспаления у пациентов ХОБЛ на фоне терапии β2-агонистами короткого действия. XI Всероссийский конгресс «Человек и медицина». Тезисы, 2004, с. 278.
  7. Цветкова О.А., Воронкова О.О. Роль провоспалительных цитокинов в прогрессировании ХОБЛ и их динамика на фоне длительной бронхолитической терапии. Российское респираторное общество. XIV Национальный конгресс органов дыхания. Тезисы, 2004, с. 546.
  8. Ridker P. C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk. Journal of the American College of Cardiology. 2007; 49 (21): 2129-2138. doi: 10.1016/j.jacc.2007.02.052
  9. Samy N, El-Maksoud A, Khayyal A, et al. Clinical utility of biomarkers as predictors of lung function in chronic obstructive pulmonary disease. New York Science Journal. 2010; 3(3): 25-32. doi: 10.7537/marsnys030310.05
  10. Клинические рекомендации Российского респираторного общества «Хроническая обструктивная болезнь легких». 2016.- 69 с.
  11. Stockley R. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Current Medical Research and Opinion. 2009; 25(5): 1235-1245. doi: 10.1185/03007990902868971.
  12. Lange P. Chronic obstructive pulmonary disease and risk of infection. Pneumonol Alergol Pol. 2009; 77 (3):284-288.
  13. Prescott E, Lange P and Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. European Respiratory Journal. 1995; 8(8): 1333-1338. doi: 10.1183/09031936.95.08081333
  14. Vestbo J, Prescott E and Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. American Journal of Respiratory and Critical Care Medicine. 1996; 153(5): 1530-1535. doi: 10.1164/ajrccm.153.5.8630597
  15. Осадчук М.А., Зарубина Е.Г., Мишина Е.А. Роль эндотелиальной дисфункции в патогенезе сочетанных сердечно - легочных заболеваний. Клиническая медицина. 2006;(5): 31-34.
  16. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 1996; 348 (9027): 567-572. doi.org/10.1016/s0140-6736(96)02374-4
  17. Теблоев К.И., Спасский А.А., Фомина К.А., Жиляев Е.В. Факторы, влияющие на прогрессирование ХОБЛ и бронхиальной астмы. М.: Capital Press, 2015: 65.
  18. Tonnesen P, Carrozzi L, Fagestrom K.O, et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J. 2007; 29(2): 390-417. doi.org/10.1183/ 09031936.00060806

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies